A detailed history of Price T Rowe Associates Inc transactions in Fibrogen Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 117,258 shares of FGEN stock, worth $104,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117,258
Previous 111,404 5.25%
Holding current value
$104,359
Previous $99,000 178.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.73 - $2.73 $4,273 - $15,981
5,854 Added 5.25%
117,258 $276,000
Q4 2023

Feb 14, 2024

BUY
$0.38 - $0.91 $15,466 - $37,037
40,700 Added 57.56%
111,404 $99,000
Q3 2023

Nov 14, 2023

BUY
$0.79 - $2.83 $19,276 - $69,052
24,400 Added 52.7%
70,704 $62,000
Q2 2023

Aug 14, 2023

SELL
$2.49 - $20.59 $1.9 Million - $15.7 Million
-762,319 Reduced 94.27%
46,304 $126,000
Q1 2023

May 15, 2023

SELL
$15.95 - $25.18 $1.91 Million - $3.01 Million
-119,511 Reduced 12.88%
808,623 $15.1 Million
Q4 2022

Feb 14, 2023

BUY
$13.27 - $17.73 $11.9 Million - $15.9 Million
894,858 Added 2689.2%
928,134 $14.9 Million
Q3 2022

Nov 14, 2022

BUY
$11.4 - $14.6 $147,219 - $188,544
12,914 Added 63.42%
33,276 $433,000
Q2 2022

Aug 15, 2022

BUY
$7.94 - $12.96 $23,335 - $38,089
2,939 Added 16.87%
20,362 $215,000
Q1 2022

May 16, 2022

BUY
$12.02 - $16.79 $50,532 - $70,585
4,204 Added 31.8%
17,423 $209,000
Q4 2021

Feb 14, 2022

SELL
$9.93 - $15.39 $182,662 - $283,099
-18,395 Reduced 58.19%
13,219 $186,000
Q3 2021

Nov 15, 2021

SELL
$10.18 - $26.64 $4.73 Million - $12.4 Million
-464,872 Reduced 93.63%
31,614 $323,000
Q2 2021

Aug 16, 2021

SELL
$18.57 - $35.68 $26 Million - $50 Million
-1,401,581 Reduced 73.84%
496,486 $13.2 Million
Q1 2021

May 17, 2021

SELL
$31.0 - $55.72 $53.6 Million - $96.4 Million
-1,729,330 Reduced 47.67%
1,898,067 $65.9 Million
Q4 2020

Feb 16, 2021

BUY
$37.09 - $48.97 $135 Million - $178 Million
3,627,397 New
3,627,397 $135 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $83.4M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.